Author | Year | Acronym | Number of participants | Indication | Control | Ivabradine dose (bid) | AF data source |
---|---|---|---|---|---|---|---|
Tardif et al14 | 2005 | INITIATIVE | 939 | Angina | Atenolol | 7.5 mg/10 mg | Included in OOSS |
Ruzyllo et al15 | 2007 | 1195 | Angina | Amlodipine | 7.5 mg/10 mg | Included in OOSS | |
Fox et al2 | 2008 | BEAUTIFUL | 10 907 | Heart Failure | Placebo | 5 mg/7.5 mg | EMeA |
Tardif et al16 | 2009 | ASSOCIATE | 889 | Angina | Placebo | 5 mg/7.5 mg | No data |
Fasullo et al17 | 2009 | 155 | Anterior STEMI | Metoprolol | 5 mg/7.5 mg | No data | |
Swedberg et al3 | 2010 | SHIFT | 6492 | Heart Failure | Placebo | 2.5–7.5 mg | Original paper |
Nerla et al18 | 2012 | 61 | Type II diabetes | Atenolol/placebo | 5 mg | Personal communication | |
Dominguez- Rodriguez et al19 | 2012 | 27 | NSTE-ACS | Placebo | 5 mg | Personal communication | |
Cappato et al21 | 2012 | 21 | IST | Placebo | 5 mg | Personal communication | |
Villano et al22 | 2013 | 46 | Microvascular angina | Ranolazine/placebo | 5 mg | Personal communication | |
EMeA | 2005 | OOSS | 3936 | Atenolol/amlodipine/placebo | 5–10 mg | EMeA |
The AF data for the INITIATIVE study and from Ruzyllo et al were not available separately, but were included in the OOSS from the EMeA with three other studies.
AF, atrial fibrillation; bid, twice daily; EMeA, European Medicines Agency; IST, inappropriate sinus tachycardia; NSTE-ACS, non-ST elevation acute coronary syndrome; OOSS, overall oral safety set; STEMI, ST elevation myocardial infarction.
Trial acronyms: ASSOCIATE: Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. BEAUTIFUL:Ivabradine for patients with stable coronary artery disease and left ventricular dysfunction (BEAUTIFUL): a randomized, doube-blind, placebo-controlled trial. INITIATIVE: Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. SHIFT: Systolic Heart Failure Treatments with If Inhibitor Ivabradine Trial.